Use of Immunosuppressive Therapy for Sarcoidosis

NCT02356445 | Unknown

• 1 other identifier: UCincinnati
• Study Type: observational
• Target: 2,000
• Locations: 1 country
• Sites: 1

Brief Summary

Retrospective review of the outcome of use of immunosuppressive drugs in treatment of sarcoidosis

Conditions

Sarcoidosis

Outcome Measures

Primary Outcomes (1)

• Clinical Outcome

  Number of participants with improvement over two years

  2 years

Secondary Outcomes (1)

• Toxicity

  2 years

Study Arms (1)

Cytotoxic drug

Patients treated for sarcoidosis

Other: Cytotoxic drug

Interventions

Cytotoxic drug OTHER

Observe patients versus treatment type

Also known as: Methotrexate, azathioprine, infliximab, Acthar

Cytotoxic drug

Eligibility Criteria

• Age: 15 Years - 90 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

All patients with sarcoidosis treated

You may qualify if:

• Any patient treated for sarcoidosis

You may not qualify if:

• None

Sponsors & Collaborators

• University of Cincinnati: lead

Study Sites (1)

University of Cincinnati

Cincinnati, Ohio, 45267, United States

RECRUITING

Related Publications (2)

• Baughman RP, Kotzin J, Lower EE. The Value of a Patient Global Assessment in Management of Sarcoidosis. Lung. 2021 Aug;199(4):357-362. doi: 10.1007/s00408-021-00455-5. Epub 2021 Jul 13.

  PMID: 34255140 DERIVED

• Zhou Y, Lower EE, Li HP, Costea A, Attari M, Baughman RP. Cardiac Sarcoidosis: The Impact of Age and Implanted Devices on Survival. Chest. 2017 Jan;151(1):139-148. doi: 10.1016/j.chest.2016.08.1457. Epub 2016 Sep 8.

  PMID: 27614001 DERIVED

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum in some cases

MeSH Terms

Conditions

Sarcoidosis

Interventions

Cytotoxins; Methotrexate; Azathioprine; Infliximab; Adrenocorticotropic Hormone

Condition Hierarchy (Ancestors)

Lymphoproliferative Disorders; Lymphatic Diseases; Hemic and Lymphatic Diseases; Hypersensitivity, Delayed; Hypersensitivity; Immune System Diseases

Intervention Hierarchy (Ancestors)

Noxae; Toxic Actions; Chemical Actions and Uses; Aminopterin; Pterins; Pteridines; Heterocyclic Compounds, 2-Ring; Heterocyclic Compounds, Fused-Ring; Heterocyclic Compounds; Thionucleosides; Sulfur Compounds; Organic Chemicals; Mercaptopurine; Purines; Nucleosides; Nucleic Acids, Nucleotides, and Nucleosides; Antibodies, Monoclonal; Antibodies; Immunoglobulins; Immunoproteins; Blood Proteins; Proteins; Amino Acids, Peptides, and Proteins; Serum Globulins; Globulins; Melanocortins; Pro-Opiomelanocortin; Hypothalamic Hormones; Peptide Hormones; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Pituitary Hormones, Anterior; Pituitary Hormones; Neuropeptides; Peptides; Nerve Tissue Proteins

Study Officials

• Robert P Baughman, MD

  University of Cincinnati

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Robert P Baughman, MD

CONTACT

513-584-5225; bob.baughman@uc.edu

Felicia Thompson

CONTACT

513-584-5226; thompsonf@ucmail.uc.edu

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: RETROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Professor of Medicine

Study Record Dates

• First Submitted: November 3, 2014
• First Posted: February 5, 2015
• Study Start: November 1, 2014
• Primary Completion: November 1, 2018
• Study Completion: December 1, 2018
• Last Updated: August 14, 2017

Record last verified: 2017-08

Locations

US (1)